SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2016 / Cilt: 46 - Sayı: 6

The combined effects of proteasome inhibitor bortezomib with topoisomerase I and II inhibitors on topoisomerase enzymes

Emine ÖKSÜZOĞLU
Çiydem TIRINOĞLU
Barış KERİMOĞLU
Pages
1882–1888
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our results indicated that bortezomib is effective not only on proteasome but also on topoisomerase II.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: DNA topoisomerases are ubiquitous enzymes that regulate conformational changes in DNA topology during essential cellular processes, and, for this reason, have been characterized as the cellular targets of a number of anticancer drugs.
📊
Key Findings & Data:IC50 values of the drugs on topoisomerase enzymes were calculated using the S probit analysis program.
💡
Conclusion & Impact:Our results indicated that bortezomib is effective not only on proteasome but also on topoisomerase II.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: DNA topoisomerases are ubiquitous enzymes that regulate conformational changes in DNA topology during essential cellular processes, and, for this reason, have been characterized as the cellular targets of a number of anticancer drugs. Bortezomib is a powerful proteasome inhibitor used in the treatment of hematological malignancies. In this study, we investigated the inhibitory effects of bortezomib on human topoisomerase I and II enzymes both alone and in combination modes with camptothecin and etoposide. Materials and methods: The interactions of these drugs with topoisomerase enzymes were evaluated by relaxation assay in cell-free systems. IC50 values of the drugs on topoisomerase enzymes were calculated using the S probit analysis program. Results: Bortezomib showed a very weak inhibition effect on topoisomerase I (IC50 = 87.11 mM). On the other hand, it had a strong inhibitory effect on topoisomerase II (IC50 = 1.41 mM). Our results indicated that bortezomib is effective not only on proteasome but also on topoisomerase II. In addition, bortezomib possesses an increased synergistic effect when used in combination with camptothecin and etoposide than when used alone. Conclusion: The results of this study point out that these data may build a framework for combination studies with bortezomib, camptothecin, and etoposide in the treatment of cancer.

🔖

Cite This Article

ÖKSÜZOĞLU, E., TIRINOĞLU, Ç., KERİMOĞLU, B. (2022). The combined effects of proteasome inhibitor bortezomib with topoisomerase I and II inhibitors on topoisomerase enzymes. Turkish Journal of Medical Sciences, Cilt: 46 - Sayı: 6, 1882–1888. https://ajindex.com/articles/610857

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Blade J, Ciberia TM, Rosinol L. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma. Acta Oncol 2005; 44: 440-448
  2. Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 2005; 5-18
  3. Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003; 8: 508-513
  4. Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, Pazdur R. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007; 13: 5291-5294
  5. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 2011; 11: 239-253
  6. Maxwell T, Bates A. Topo 2008: DNA topoisomerases in biology and medicine. Nucleic Acids Res 2009; 37: 3
  7. Wang JC. DNA Topoisomerases. Ann Rev Biochem 1996; 65: 635-692
  8. Ting CY, Hsu CT, Hsu HT, Su JS, Chen TY, Tarn WY, Kuo YH, Jacqueline WP, Liu LF, Hwang J. Isodiospyrin as a novel human DNA topoisomerase I inhibitor. Biochem Pharm 2003; 66: 1981-1991
  9. Nitiss JL. Investigating the biological function of DNA topoisomerases in eukaryotic cells. Biochim Biophys Acta 998; 1400: 63-81
  10. Champoux JJ. DNA topoisomerases: structure, function and mechanism. Annu Rev Biochem 2001; 70: 369-413
  11. Pommier Y. Drugging topoisomerases: lessons and challenges. ACS Chem Biol 2013; 8: 82-95
  12. Seaton A, Higgins C, Mann J, Baron A, Bailly C, Neidle S, Van Den Berg H. Mechanistic and anti-proliferate studies of two novel, biologically active bis-Benzimidazoles. Eur J Cancer 2003; 39: 2548-2555
  13. Hsiang YH, Hertzberg R, Hecht S, Liu LF. CPT induces proteinlinked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260: 14873-14878
  14. Svejstrup JQ, Christiansen K, Gromova II, Andersen AH, Westergaard O. New technique for uncoupling the cleavage and religation reactions of eukaryotic topoisomerase I: the mode of action of CPT at a specific recognition site. J Mol Biol 1991; 222: 669-678
  15. Baldwin, EL, Osheroff, N. Etoposide, topoisomerase II and cancer. Curr Med Chem-Anti-Cancer Agents 2005; 5: 363-372
  16. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440-446
  17. Halligan BD, Edwards KA, Liu LF. Purification and characterization of type II DNA topoisomerase from bovine c